{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:18:46Z","timestamp":1786115926788,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04517-z","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:01:01Z","timestamp":1785996061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-6769","authenticated-orcid":false,"given":"Antonella","family":"Ferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Eccher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Caldara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cantarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Campregher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"De Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Dipasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lazzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Monteverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Armatura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenza","family":"De Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvi","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"4517_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"key":"4517_CR2","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res"},{"key":"4517_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1049\u201360. https:\/\/doi.org\/10.1200\/JCO.2015.63.1010.","journal-title":"J Clin Oncol"},{"key":"4517_CR4","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414\u201322. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823.","journal-title":"J Clin Oncol"},{"key":"4517_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1200\/JCO.2007.11.5352","volume":"26","author":"JS Jeruss","year":"2008","unstructured":"Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26:246\u201352. https:\/\/doi.org\/10.1200\/JCO.2007.11.5352.","journal-title":"J Clin Oncol"},{"key":"4517_CR6","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","volume":"29","author":"EA Mittendorf","year":"2011","unstructured":"Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:1956\u201362. https:\/\/doi.org\/10.1200\/JCO.2010.31.8469.","journal-title":"J Clin Oncol"},{"key":"4517_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"key":"4517_CR8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"key":"4517_CR9","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","volume":"28","author":"T Fujii","year":"2017","unstructured":"Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017;28:2420\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx397.","journal-title":"Ann Oncol"},{"key":"4517_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"4517_CR11","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond ME, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists guideline update. J Clin Oncol. 2023;41:3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol"},{"key":"4517_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2 C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123\u201335. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.016.","journal-title":"Semin Cancer Biol"},{"key":"4517_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-013-2620-0","volume":"140","author":"EH Lips","year":"2013","unstructured":"Lips EH, Mulder L, de Ronde JJ, Mandjes IAM, Koolen BB, Wessels LFA, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140:63\u201371. https:\/\/doi.org\/10.1007\/s10549-013-2620-0.","journal-title":"Breast Cancer Res Treat"},{"key":"4517_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","volume":"28","author":"E Provenzano","year":"2015","unstructured":"Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015;28:1185\u2013201. https:\/\/doi.org\/10.1038\/modpathol.2015.74.","journal-title":"Mod Pathol"},{"key":"4517_CR15","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.ejca.2010.07.043","volume":"46","author":"N Houssami","year":"2010","unstructured":"Houssami N, Macaskill P, Marinovich ML, Dixon JM, Irwig L, Brennan ME, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.07.043.","journal-title":"Eur J Cancer"},{"key":"4517_CR16","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)32381-3.","journal-title":"Lancet"},{"key":"4517_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-014-2861-6","volume":"144","author":"S Loibl","year":"2014","unstructured":"Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144:153\u201362. https:\/\/doi.org\/10.1007\/s10549-014-2861-6.","journal-title":"Breast Cancer Res Treat"},{"key":"4517_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2007","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A\u2019Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167\u201370. https:\/\/doi.org\/10.1093\/jnci\/djk020.","journal-title":"J Natl Cancer Inst"},{"key":"4517_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pathol.2016.11.006","volume":"49","author":"F Penault-Llorca","year":"2017","unstructured":"Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49:166\u201371. https:\/\/doi.org\/10.1016\/j.pathol.2016.11.006.","journal-title":"Pathology"},{"key":"4517_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jnci\/djn309","volume":"100","author":"MJ Ellis","year":"2008","unstructured":"Ellis MJ, Tao Y, Luo J, A\u2019Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:1380\u20138. https:\/\/doi.org\/10.1093\/jnci\/djn309.","journal-title":"J Natl Cancer Inst"},{"key":"4517_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383. https:\/\/doi.org\/10.1056\/NEJMoa0910383.","journal-title":"N Engl J Med"},{"key":"4517_CR22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1630\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9.","journal-title":"Lancet Oncol"},{"key":"4517_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9.","journal-title":"Lancet Oncol"},{"key":"4517_CR24","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"},{"key":"4517_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.021.","journal-title":"Eur J Cancer"},{"key":"4517_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211009003","volume":"13","author":"HF Gao","year":"2021","unstructured":"Gao HF, Wu Z, Lin Y, Song XY, Cao Y, Chen QJ, et al. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. Ther Adv Med Oncol. 2021;13:17588359211009003. https:\/\/doi.org\/10.1177\/17588359211009003.","journal-title":"Ther Adv Med Oncol"},{"key":"4517_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211006948","volume":"13","author":"J Zhang","year":"2021","unstructured":"Zhang J, Yu Y, Lin Y, Kang S, Lv X, Liu Y, et al. Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. Ther Adv Med Oncol. 2021;13:17588359211006948. https:\/\/doi.org\/10.1177\/17588359211006948.","journal-title":"Ther Adv Med Oncol"},{"key":"4517_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"4517_CR29","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2409932.","journal-title":"N Engl J Med"},{"key":"4517_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014805.pub2","volume":"2023","author":"SR Mason","year":"2023","unstructured":"Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A. Platinum-based chemotherapy for early triple-negative breast cancer. Cochrane Database Syst Rev. 2023;2023:CD014805. https:\/\/doi.org\/10.1002\/14651858.CD014805.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"4517_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO-25-01023","volume":"44","author":"S Gupta","year":"2026","unstructured":"Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, et al. Addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer: a phase III randomized controlled trial. J Clin Oncol. 2026;44:9\u201319. https:\/\/doi.org\/10.1200\/JCO-25-01023.","journal-title":"J Clin Oncol"},{"key":"4517_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00477-z","volume":"8","author":"S Loibl","year":"2022","unstructured":"Loibl S, Huang CS, Mano MS, Mamounas EP, Geyer CE, Untch M, et al. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. NPJ Breast Cancer. 2022;8:106. https:\/\/doi.org\/10.1038\/s41523-022-00477-z.","journal-title":"NPJ Breast Cancer"},{"key":"4517_CR33","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med"},{"key":"4517_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159.","journal-title":"Ann Oncol"},{"key":"4517_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514661","author":"S Loibl","year":"2025","unstructured":"Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2514661.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04517-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:01:02Z","timestamp":1785996062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04517-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":35,"alternative-id":["4517"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04517-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee. Given the retrospective nature of the study and the use of anonymized patient data, the requirement for informed consent was waived.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient consent was waived due to the retrospective nature of the study and the use of anonymized patient data.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}